CoChat

Avoiding Drug Resistance in HIV Reverse Transcriptase

Open access

The DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.

Abstract

HIV reverse transcriptase (RT) is an enzyme that plays a major role in the replication cycle of HIV and has been a key target of anti-HIV drug development efforts. Because of the high genetic diversity of the virus, mutations in RT can impart resistance to various RT inhibitors. As the prevalence of drug resistance mutations is on the rise, it is necessary to design strategies that will lead to drugs less susceptible to resistance. Here we provide an in-depth review of HIV reverse transcriptase, current RT inhibitors, novel RT inhibitors, and mechanisms of drug resistance. We also present novel strategies that can be useful to overcome RT's ability to escape therapies through drug resistance. While resistance may not be completely avoidable, designing drugs based on the strategies and principles discussed in this review could decrease the prevalence of drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.chemrev.0c00967

Cites

305 of 305 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 305 references

Research works printed but not linked: 8

  1. Vogt V., 1997, Retroviruses
  2. Telesnitsky A., 1997, Retroviruses
  3. Volberding P., 2002, AIDS Read., 12, 349
  4. D’Aquila R. T., 2003, Top HIV Med., 11, 92
  5. Kirby K. A., 2011, Cell. Mol. Biol., 57, 40
  6. Grobler, J. A.; Fillgrove, K.; Hazuda, D.; Huang, Q.; Lai, M. T.; Matthews, R. P.; Rudd, D. J.; Vargo, R. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW. In Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA , 2019; 481, http://www.croiconference.org/sessions/mk-8591-potency-and-pk-provide-high-inhibitory-quotients-low-doses-qd-and-qw (accessed 2020-07-13).
  7. Bekker, L-G.; Li, S. S.; Tolly, B.; Marzinke, M. A.; Mgodi, N.; Justman, J. E.; Swaminathan, S.; Adeyeye, A.; Farrior, J. H.; Sista, N. Hptn 076:Tmc278 ls safe, tolarable, and acceptable for HIV preexposure prophylaxis. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA , 2017.
  8. 2011, Janssen Products

Cited by

See all 117

Metadata

Authors
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G.
Affiliations
Emory University (US)
Corresponding author
Sarafianos, Stefan G.
Venue
Chemical Reviews
Published
2021-01-28
Volume
121
Issue
6
Pages
3271-3296
ISSN
  • 0009-2665 (ISSN-L)
  • 1520-6890
OpenAlex
W3125954347
Cited by
106
References
305
Citations by year
2026: 15 · 2025: 22 · 2024: 27 · 2023: 17 · 2022: 18 · 2021: 7
FWCI
2.28
Type
journal article
Language
en
Open access
Locations
  • Chemical Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases (R01 AI121315, R37 AI076119, U54 AI150472)
  • National Institute of General Medical Sciences (R01 GM118012, T32 GM008367)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
HIV reverse transcriptase, drug resistance, reverse transcriptase inhibitors, resistance mutations, HIV drug development, antiretroviral therapy
MeSH terms
Humans, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Virus Replication, Drug Design, Signal Transduction, HIV-1, HIV Infections, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Avoiding Drug Resistance in HIV Reverse Transcriptase. https://app.cochat.ai/papers/10.1021/acs.chemrev.0c00967
The paper
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021). Avoiding Drug Resistance in HIV Reverse Transcriptase. Chemical Reviews. https://doi.org/10.1021/acs.chemrev.0c00967

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.